These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 8682157)
1. Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study. Peters H; Fischer C; Bogner U; Reiners C; Schleusener H Eur J Clin Invest; 1996 Jan; 26(1):59-63. PubMed ID: 8682157 [TBL] [Abstract][Full Text] [Related]
2. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554 [TBL] [Abstract][Full Text] [Related]
3. Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Peters H; Fischer C; Bogner U; Reiners C; Schleusener H Eur J Clin Invest; 1995 Mar; 25(3):186-93. PubMed ID: 7781666 [TBL] [Abstract][Full Text] [Related]
4. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656 [TBL] [Abstract][Full Text] [Related]
5. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I. Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745 [TBL] [Abstract][Full Text] [Related]
6. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose. Haase A; Bähre M; Lauer I; Meller B; Richter E Exp Clin Endocrinol Diabetes; 2000; 108(2):133-7. PubMed ID: 10826521 [TBL] [Abstract][Full Text] [Related]
8. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism. Franklyn JA; Daykin J; Holder R; Sheppard MC QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667 [TBL] [Abstract][Full Text] [Related]
9. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism. Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459 [TBL] [Abstract][Full Text] [Related]
10. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents]. Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Graves' hyperthyroidism with radioiodine: results of a prospective randomized study. Peters H; Fischer C; Bogner U; Reiners C; Schleusener H Thyroid; 1997 Apr; 7(2):247-51. PubMed ID: 9133695 [TBL] [Abstract][Full Text] [Related]
12. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism. Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167 [TBL] [Abstract][Full Text] [Related]
13. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study. Howarth D; Epstein M; Lan L; Tan P; Booker J Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491 [TBL] [Abstract][Full Text] [Related]
14. [Therapeutic results of radioiodine therapy of hyperthyroid thyroid gland diseases]. Debrand-Passard A; Barzen G; Richter W; Wenzel KW; Felix R Med Klin (Munich); 1994 Jun; 89(6):319-23. PubMed ID: 8072455 [TBL] [Abstract][Full Text] [Related]
15. Radioiodine therapy for Graves' disease - retrospective analysis of efficacy factors. Szumowski P; Abdelrazek S; Kociura Sawicka A; Mojsak M; Kostecki J; Sykała M; Myśliwiec J Endokrynol Pol; 2015; 66(2):126-31. PubMed ID: 25931042 [TBL] [Abstract][Full Text] [Related]
16. Functional results of radioiodine therapy with a 300-Gy absorbed dose in Graves' disease. Willemsen UF; Knesewitsch P; Kreisig T; Pickardt CR; Kirsch CM Eur J Nucl Med; 1993 Nov; 20(11):1051-5. PubMed ID: 8287872 [TBL] [Abstract][Full Text] [Related]
17. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414 [TBL] [Abstract][Full Text] [Related]
18. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose]. Bakker SC; Zanin DE; Zweers EJ Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370 [TBL] [Abstract][Full Text] [Related]
19. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease. Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Hansen BM; Søe-Jensen P; Hansen JM J Intern Med; 1995 Dec; 238(6):491-7. PubMed ID: 9422034 [TBL] [Abstract][Full Text] [Related]
20. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary? Bajnok L; Mezosi E; Nagy E; Szabo J; Sztojka I; Varga J; Galuska L; Leovey A Thyroid; 1999 Sep; 9(9):865-9. PubMed ID: 10524564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]